Opinion

Video

Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

Author(s):

Neal Shore, MD

A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.

Video content above is prompted by the following question(s):

  • What are the potential advantages of the novel gene therapy nadofaragenefiradenovec compared to standard-of-care therapies for patients with BCG-unresponsive NMIBC? Discuss the clinical significance of the 5-year bladder preservation and overall survival rates reported.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
CK Wang, MD, COTA
Eric Lander, MD
Eric Lander, MD
David Awad, PharmD, BCOP
Related Content
Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
June 29th 2025

Decline in SCLC Incidence Expected to Accelerate Through 2050

Jared Kaltwasser
The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Gender rights | Image Credit: © Nadzeya-stock.adobe.com
June 23rd 2025

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

Maggie L. Shaw
This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
June 19th 2025

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

Jared Kaltwasser
Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.
The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
June 18th 2025

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

Jared Kaltwasser
A teledermatology program in Georgia helped identify patients with skin lesions that warranted in-person follow-up with a physician.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo